Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40UHG | ISIN: US7389201077 | Ticker-Symbol:
NASDAQ
06.06.25 | 21:58
0,372 US-Dollar
+9,66 % +0,033
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
ASPIRE BIOPHARMA HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
ASPIRE BIOPHARMA HOLDINGS INC 5-Tage-Chart

Aktuelle News zur ASPIRE BIOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
28.05.Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB, its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025303Sublingual nano technology delivers caffeine rapidly to the blood stream, bringing its unique disruptive benefits to the Pre-workout marketInitial production has commenced with six flavor optionsExpanded...
► Artikel lesen
20.05.Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation241Trial marks key milestone in driving pipeline progressPhase 1 trial scheduled for completion mid-June 2025Topline data from High-Dose Aspirin Trail anticipated early in 3Q with the potential to support...
► Artikel lesen
14.05.Aspire Biopharma Holdings, Inc. - 10-Q, Quarterly Report1
13.05.Aspire Biopharma announces resale of up to 11.26M shares3
ASPIRE BIOPHARMA Aktie jetzt für 0€ handeln
13.05.Aspire Biopharma Holdings, Inc. - S-1, General form for registration of securities1
08.05.Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21185HUMACAO, PUERTO RICO AND NEW YORK, NY / ACCESS Newswire / May 8, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug...
► Artikel lesen
29.04.Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval for In-Human Clinical Trial of an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation288Company achieves another milestone relating to its clinical trial strategy HUMACAO, PR and NEW YORK, NY / ACCESS Newswire / April 29, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or...
► Artikel lesen
18.04.Aspire Biopharma Holdings, Inc. - 8-K, Current Report2
14.04.Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17225HUMACAO, PR AND NEW YORK, NY / ACCESS Newswire / April 14, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery...
► Artikel lesen
11.04.Aspire Biopharma beginnt mit der Produktion von Pre-Workout-Nahrungsergänzungsmitteln1
11.04.Aspire Biopharma starts production of pre-workout supplement2
11.04.Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement196Plans to conduct consumer and safety testing during second quarter 2025Desert Stream Inc.,a leading private label manufacturer in the health and wellness industry, performing initial productionSingle...
► Artikel lesen
09.04.Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation264One clinical trial site activatedPatient enrollment expected in AprilTrial designed to evaluate safety, pharmacokinetics and pharmacodynamics, of Aspire's sublingual aspirin productAspire anticipates...
► Artikel lesen
09.04.Aspire Biopharma Holdings, Inc. - S-1, General form for registration of securities4
07.04.Aspire Biopharma Holdings, Inc. - 10-K, Annual Report1
31.03.Aspire Biopharma Holdings, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT4051
20.03.Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin271Subsequent phase involves completion of chemistry, manufacturing, and controls (CMC) testing for data to support FDA submissionCompany expects to commence bioavailability study in April 2025Aspire intends...
► Artikel lesen
13.03.Aspire Biopharma treibt Patentanmeldungen für Arzneimittelverabreichungstechnologie voran5
13.03.Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform269HUMACAO, PUERTO RICO AND NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug...
► Artikel lesen
11.03.SCD Media, LLC: An Interview with the CEO: How Aspire Biopharma is Disrupting a $100 Billion Market with Sublingual Innovation211New York, New York--(Newsfile Corp. - March 11, 2025) - Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP) ("Aspire" or the "Company") is revolutionizing drug delivery through its proprietary sublingual...
► Artikel lesen
Weiter >>
34 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1